% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • mikeadd Oct 19, 2011 9:31 PM Flag

    Latest from JPM Securities via BioRunUp via Twitter

    OPTR Script trend growing: Optimer Pharma: Prescription trends show growth for Dificid in September; reit Outperform - JMP Securities (13.87 +0.07)
    JMP Securities reits their Outperform and $20 tgt on OPTR after prescription trends show growth for Dificid in September. Firm says their analysis of Rx audit data for the month of September demonstrates that sales from institutions such as hospitals increased 10% month over month to $1.34 mln from $1.22 mln in August. They note that retail demand for Dificid accounted for 60% of sales in the month of September, up from 40% at the start of the launch, with 67% of retail demand from commercial payors, and demonstrated 37% month over month growth.